Katherine Roguske, MA Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 160 3rd Ave Nw, Milaca, MN 56353 Phone: 320-983-2335 |
Noel Willis, MS, LMFT Marriage & Family Therapist Medicare: Medicare Enrolled Practice Location: 150 10th St Nw Ste 2, Milaca, MN 56353 Phone: 320-983-8033 Fax: 651-342-8029 |
Kelsey Ann Gruba, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 15010th St Nw, Ste 2, Milaca, MN 56353 Phone: 320-983-2335 Fax: 651-342-8029 |
Amy Boldt, LMFT Marriage & Family Therapist Medicare: Medicare Enrolled Practice Location: 150 10th St Nw Ste 2, Milaca, MN 56353 Phone: 320-983-2335 Fax: 651-342-8029 |
Amber Hosie, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 150 10th St Nw Ste 2, Milaca, MN 56353 Phone: 320-983-2335 Fax: 651-342-8029 |
News Archive
"Giving vitamin A supplements to children under the age of five in developing countries could save 600,000 lives a year, researchers claim" in a paper published Thursday in the British Medical Journal, BBC News reports.
In the current issue of Cardiovascular Innovations and Applications (Special Issue on Women's Cardiovascular Health, Volume 3, Number 4, 2019, Guest Editor Gladys P. Velarde) pp. 375-389(15); DOI: https://doi.org/10.15212/CVIA.2019.0007 Viviany R. Taqueti from the Cardiovascular Imaging Program, Heart and Vascular Center, Division of Cardiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA reviews novel imaging approaches for the diagnosis of stable ischemic heart disease in women.
Extremely preterm infants can suffer from a life-threatening inflammation of the gut. A new clinical study has shown that supplements of a lactic acid bacterium may have positive effects by increasing the diversity of intestinal bacteria in these infants.
Janssen-Cilag International NV today announced that data from a post-hoc analysis of the Phase 3 COU-AA-302 trial showed that ZYTIGA (abiraterone acetate) plus prednisone provided an 11.8 months overall survival (OS) benefit (53.6 months vs 41.8 months; HR = 0.61 [95% CI, 0.43-0.87]; p = 0.0055), compared to an active control of placebo plus prednisone, in men with early and less aggressive chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).
› Verified 7 days ago